Introduction
The success of gene therapy is largely dependent on the development of a vector or vehicle that can selectively and efficiently deliver a gene to target cells with minimal toxicity. Viruses are efficient in transducing cells. However, the safety concerns regarding the use of virus in humans make nonviral delivery systems an attractive alternative. Nonviral vectors are particularly suitable with respect to simplicity of use, ease of large-scale production and lack of specific immune response. Recently, several novel nonviral vectors have been developed that approach viruses with respect to transfection efficiency. A variety of nonviral delivery systems that can be used for gene therapy in different clinical settings are also available.
Naked DNA
The simplest approach to nonviral delivery systems is direct gene transfer with naked plasmid DNA. Following the landmark discovery by Wolff and colleagues 1 that reporter genes could be expressed following direct injection into skeletal muscle, there has been an intense interest in generating antiviral immune response by intramuscular injection of a plasmid encoding a viral antigen. These immune responses are sufficient to protect animals from a wide variety of live infectious agents, leading to a new class of therapeutic modality called 'DNA vaccines'. 2 Intramuscular injection of plasmid DNA has also been used to express other pharmacologically active molecules including erythropoietin and leptin. Skin, some tumors and certain immune cells including dendritic cells are also susceptible to naked DNA-mediated gene transfer. This has led to another active research area: tumor vaccination. 3 Antitumor immunity can be induced by intratissue injection of a variety of cytokines genes or tumor inhibitory genes. In the latter case, antitumor effect is achieved by directly inhibiting tumor growth and/or elicit-
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ing an immune response subsequent to the uptake of apoptotic tumor cells by antigen-presenting cells. Intravascular injection of plasmid DNA generally results in limited gene expression in all major organs. However, rapid injection of plasmid DNA in a large volume (1.5 to 3.0 ml) through the portal or tail vein can give rise to high level gene expression in mice, particularly in the liver. 4 The level of gene expression is close to or higher than that achieved by i.v. administration of adenoviral vectors. While this procedure can hardly be translated into clinical applications, it offers a simple protocol to analyze gene function in intact mice.
Several approaches have been developed to enhance the efficiency of gene transfer via naked DNA including gene gun 5 and electroporation. 6 These physical approaches allow DNA directly to penetrate cell membrane and bypass endosome/lysosome, thus avoiding enzymatic degradation. DNA may also directly reach the nucleus by gene gun. It has been reported that intramuscular injection of plasmid DNA followed by electroporation results in an impressive level of gene expression. 7 Recently, it has been shown that polymers that weakly interact with DNA such as PVP can also improve the efficiency of gene transfer by direct intramuscular injection. 8 These polymers are supposed to offer protection against enzymatic degradation. They may also serve as a depot system allowing DNA to be released over a prolonged period of time. However, cationic polymers or cationic lipids that efficiently interact with and condense DNA generally have a negative effect on gene expression via intramuscular injection. These observations together with the fact that naked DNA is not active in vitro suggest a different mechanism of cellular uptake of DNA in vivo. A better understanding of the mechanism of cellular uptake of plasmid DNA in vivo should further improve the efficiency of naked DNA-mediated gene transfer and promote its clinical applications.
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Cationic lipids
While gene expression can be achieved by direct intratissue injection of naked plasmid DNA, gene transfer via other routes of administration such as intratracheal and intravenous injection will generally require the use of a delivery vector or vehicle. Various types of synthetic vectors have been developed for gene transfer. Among these, cationic lipid-and polymer-based systems have been the most extensively studied. Since the first description of successful in vitro transfection with cationic lipid by Felgner et al in 1987, 9 the last 10 years have witnessed substantial progress in the application of synthetic gene delivery systems. One of the aspects of this progress is the synthesis of new cationic lipids. 10, 11 Following some early studies on the structure-activity relationship of cationic lipids, it was hoped that some 'magic' lipids could be discovered. While some new lipids are more efficient than the first-generation cationic lipids in gene transfer, the goal of finding a 'magic' lipid has been far from being realized. Doubts remain whether a truly 'magic' lipid can ever be discovered. Another lesson learned from these studies is that there is a discrepancy between in vitro and in vivo transfection conditions. The in vivo transfection efficiency of a lipid is also dependent on the administration route. Thus, optimization of a vector has to be individualized according to each clinical setting. This situation renders further vector development a difficult task.
Cationic lipid/DNA complexes (lipoplexes) have been used in several clinical trails for the treatment of cancer and cystic fibrosis. 12, 13 These studies by and large validate the concept of human gene therapy. Lipoplexes were proven to be safe when locally delivered at relatively low doses. However, no long-term safety studies have been performed. Also, the efficiency of lipidic vectors needs to be improved before cationic lipid-mediated gene transfer can become standard practice in the clinic.
The low efficiency of gene transfer in vivo has called for more fundamental studies into the molecular and cellular barriers in gene transfer, and the biological interaction of vectors with the host. Over the last few years progress has been made in elucidating the structures of lipoplexes. Electron microscopic observation of various lipoplexes reveals a variety of complexes and their aggregates, with a possibility of attached tubular structures. These findings suggest that the interaction between DNA and cationic liposomes is a self-assembly process that is triggered by DNA-mediated fusion of liposomes and involves a large-scale lipid rearrangement. This was recently confirmed by small-angle X-ray scattering (SAXS) experiments in which two types of periodic structures were revealed.
14 The larger periodicity of typically 5.5-6.5 nm was attributed to planar arrays of lipid bilayers with DNA sandwiched in between, while the smaller and less pronounced periodicity of 3-4 nm was attributed to the separation of the DNA helices within the plane of bilayered sandwich.
14 This model was supported by atomic force microscopy observations of two-dimensional (short range order) DNA condensation on deposited cationic bilayers. While the biological implications of the different structures remain to be understood, the above studies clearly suggest that plasmid DNA is not efficiently condensed especially when a monovalent cationic lipid is used.
With the advancement in imaging technology and in the ability of labeling intact, biologically active plasmid DNA, there have been more studies addressing the mechanism and cellular barriers of transfection. Cellular uptake represents the first barrier to cell transfection. It is generally accepted that the lipoplex is taken up by cells mainly through endocytosis although some studies suggest that the complex can directly penetrate the cell membrane. The molecules on the cell surface that are responsible for the interaction with lipoplexes have not been thoroughly defined. Proteoglycans (PGs) on the cell membrane appear to play an important role: cells deficient in PG synthesis are more difficult to transfect. Adding a targeting ligand to lipoplex via a covalent or non-covalent linkage can improve transfection efficiency. The second barrier to cell transfection is the translocation of plasmid DNA from endosome to the cytoplasm. Fusion appears to be involved in the release of DNA from endosome as inclusion of a fusogenic helper lipid such as DOPE improves transfection. Cationic lipids may also facilitate DNA release through their detergent and/or buffering properties. In an effort to improve transfection efficiency further, several other methods have been developed to facilitate cytoplasmic release of DNA. One of the approaches uses fusogenic peptides. Several such peptides that are highly efficient in enhancing transfection have been designed. The key limiting factor in transfection is inefficient nuclear transport of the plasmid DNA. While the mechanism of nuclear transport of plasmid DNA is not clear, several studies suggest that the nuclear localization signal (NLS)-mediated pathway is involved. The efficiency of DNA import is largely dependent on its size. However, the conformation of the DNA seems also to play a role. Linear plasmid DNA appears to be translocated into nucleus more efficiently than plasmid DNA of other configurations. Attempts to improve nuclear transport of DNA by incorporating classical peptide or nucleotide signal sequences into the vector system have only met with limited success. Interestingly, a recent study by Subramanian et al 15 showed that the inclusion of a nonclassical NLS containing the M9 sequence of heterogeneous nuclear ribonucleoprotein (hnRNP) increased the lipofection efficiency of bovine aortic endothelial cells by 63-fold. The plasmid DNA used in this study was 7.2 kb and it remains unknown whether there is a size limitation in M9-assisted transfection. Whether this approach is applicable to other types of cells is also not known. Recently, a T7-based cytoplasmic expression system has been evaluated as an alternative approach to avoid the nuclear barrier. Eventually, a gene transfer protocol employing both nuclear and cytoplasmic expression systems could be utilized to improve transfection efficiency further.
One of the drawbacks of nonviral vector is the relatively short duration of gene expression. Unfortunately, little is understood about the fate of plasmid DNA after it reaches the nucleus. In particular, little is known about the mechanism by which gene expression is shut off. Despite these undisclosed mysteries, several studies have shown that the efficiency of expression plasmid can be significantly improved by optimizing promoters, enhancers, introns, terminator sequences, and codon usage. In addition, episomal vectors have been developed to improve the expression efficiency further as well as the duration of gene expression. The last few years have also seen progress in the development of gene switch systems. This progress, together with the advancement in the development of tissue-specific vehicles, will allow nonviral gene therapy to achieve maximal therapeutic effects while minimizing undesired side-effects.
The mechanism of in vivo gene transfer varies depending on the route of administration. Most likely, the physical properties of lipoplex will change after in vivo administration. The extent of this change may be related to its interaction with biological fluids. When there is limited contact with biological fluids such as with an intratumor injection, the lipoplex may not change appreciably in its physical properties before it encounters the tumor cells. In contrast, when lipoplex is administered i.v., its size, structure, and net charge is expected to change significantly before it reaches the target. Recently, more information has accumulated regarding how serum directly affects the biophysical properties and in vivo transfection efficiency of lipoplex. 16 Initially, serum causes lipoplex to aggregate with further interaction causing its disintegration, resulting in DNA release and degradation. This serum effect appears to be a general phenomenon, however, the rate of aggregation and subsequent disintegration is largely dependent on the structure of cationic and helper lipids. These results appear to explain why cationic lipidic vectors of different lipid compositions have a dramatic difference in transfection efficiency following i.v. administration. They also highlight the negative effect of serum on cationic lipidmediated intravenous gene delivery. Other barriers to systemic gene delivery include the rapid clearance of lipoplex by the reticuloendothelial system (RES) and the lack of target specificity.
Improved understanding of the mechanism of transfection and the interaction of lipidic vectors with biological fluids has led to the development of several novel formulations that are more efficient in vivo. We have discovered that by incorporating into lipoplex small amounts of a polymer such as polylysine or protamine, we can generate virus-like particles that are highly efficient in vitro and in vivo. 17 Recently, empirical optimization of nonviral vectors has also led to the development of several lipidic vectors that are highly efficient in transfecting lungs upon i.v. injection. 18 Lung transfection is achieved primarily through the aggregation of lipoplex following exposure to blood. Due to their relatively large size, the aggregates are entrapped in the pulmonary vasculature allowing for an efficient interaction with target cells (endothelial cells). Systemic administration of cationic lipidic vectors holds promises for the treatment of several pulmonary diseases including pulmonary metastases, pulmonary hypertension and acute respiratory distress syndrome. Despite some progress, current lipidic vectors are still inefficient in active targeting of genes to distant tissues. Efforts to improve these vectors include modification of their surface to improve their biocompatibility with biological fluids and tissue specificity, and inclusion of active components that help to overcome the cellular barriers in transfection after the vectors reach the target tissues.
Polyplex (molecular conjugate)
Another class of synthetic vectors that have been actively studied are cationic polymer-based gene delivery systems. Compared with cationic lipids, cationic polymers Gene Therapy are more efficient in condensing DNA. Many different types of polymers have been evaluated as gene delivery vehicles. Among them, polyethylenimines (PEI) are the most promising. 19 PEI can mediate efficient gene transfer without the use of an endosome-disruption component possibly due to its intrinsic endosome-buffering property. PEI has been used for in vivo gene transfer via different routes of administration such as lung instillation, kidney perfusion, intracerebral injection and i.v. administration. Targeted gene delivery has also been reported by conjugating a ligand to PEI. Interestingly, PEI of different molecular weights or isoforms (branched or linear) differ with respect to their in vivo transfection efficiency and toxicity. Further study on the structure-function relationship may lead to the discovery of a new class of polymers that are more efficient and less toxic in vivo.
Natural biopolymers such as gelatin and chitosan have been previously used to prepare drug-loaded microspheres. Recent studies have shown that these polymers can also form stable nanoparticles upon mixing with DNA. 20 Improved gene expression has been observed as compared with naked DNA when these DNA nanoparticles are administered intratracheally, intramuscularly or intragastrically. The latter study creates an opportunity of oral vaccination using these DNA nanoparticles.
RNA/DNA chimera for targeted gene repair
A new gene therapy approach has recently been introduced that is based on targeted correction of diseased mutations by mismatch repair. 21 This involves the delivery into diseased cells of a chimeric RNA:DNA oligonucleotide. The chimeric molecule is designed so that it aligns in perfect register with a specified genome target, with the exception of a single base pair mismatch in the region of the pentameric stretch of DNA. The single mismatched nucleotide is then recognized by endogenous DNA repair system resulting in alteration of the DNA sequence of the targeted gene. Due to the relatively small size of RNA:DNA oligonucleotide, the requirements for vectors designed for its in vivo delivery are less stringent. The oligonucleotide can form complexes with cationic lipids or polymers through electrostatic interactions, or can be encapsulated into neutral or anionic liposomes. A targeting ligand can also be included to render the vector tissue-specific. This technology has been successful in correcting a specific chromosomal mutation in several genes in vitro. Systemic administration of an RNA:DNA oligonucleotide formulated in a nonviral vector led to a genotypic change in about 50% of hepatocytes in a rat model of Crigler-Najjar syndrome with a corresponding reduction in serum bilirubin level. 22 It has been proposed that the deletion or addition of one nucleotide at the target sequence might also be achieved by this approach. So far, it remains unknown whether genetic diseases that involve mutation (or deletion) of more than one nucleotide can be treated by this method.
CpG immunostimulatory motifs
Early animal and clinical studies suggested that lipoplexes were nontoxic and induced minimal, if any, inflammation when limited amounts of lipoplexes were used. However, several studies have demonstrated that intratracheal instillation of lipoplex into mouse lung induces a dose-dependent pulmonary inflammation along with cytokine production. 23 We have recently shown that i.v. administration of DNA complexed with cationic lipidic vectors also triggers high level production of cytokines such as INF-␥ and TNF-␣. 24 These cytokines not only cause toxicity to the treated mice but also inhibit transgene expression. 24 While cationic lipids play a synergistic role, the major component that is responsible for cytokine induction is unmethylated CpG dinucleotides in the plasmid DNA. The role of CpG motifs in immune responses has been extensively studied and CpG-containing oligonucleotides have been purposely used as an adjuvant in immunization. 25, 26 However, it was not until recently that the negative role of CpG in plasmid DNAmediated gene transfer has caught our attention. Efforts to overcome this problem include modification of plasmid DNA to reduce the number of CpG motifs and the use of immunosuppressants. Improving the tissue specificity of the delivery vehicle can also decrease the immune response by decreasing the nonspecific interaction of CpG-containing DNA with immune cells. It should be noted that the complex-induced immune response is nonspecific and repeated dosing is still feasible given a sufficient time for recovery between injections. The recovery period can be further shortened when the cytokine response is controlled by immunosuppressant.
Conclusion
The science of nonviral gene delivery is still in its infancy. Further improvement of the delivery system will continuously rely on a better understanding of the cellular and in vivo barriers in gene transfer. In addition, information from clinical applications of a nonviral system might provide new insights into the direction of future research. As different approaches are explored and new developments are introduced, we anticipate that significantly improved delivery systems will emerge. Delivery systems that confer higher levels of gene expression with minimal toxicity in vivo should yield increasingly successful clinical outcomes.
